HR Execs on the Move

Ancillare

www.ancillare.com

 
Ancillary Supply Chain, Simplified Ancillare is the leader in end-to-end global clinical trial ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations. Ancillare is the first organization of its kind with an exclusive focus on the global clinical trial ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Midwest Eye Consultants

Midwest Eye Consultants provides total eye care from eye health exams to the treatment of eye diseases. See our locations page to find an office near you.

Tiber Laboratories

Tiber Laboratories is a Suwanee, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LGM Pharma

LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities and expert regulatory support.

Flora Growth

Leading The Future of Cannabis

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.